by Anand Patadiya | Sep 20, 2024
Safety and tolerability to be determined at up to 10 study sites in the United States and Canada CAMBRIDGE, MA – March 5, 2024 – Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced the first...
by Anand Patadiya | Sep 20, 2024
March 26, 2024 (Cambridge, MA) – Ankyra Therapeutics and Jenga Biosciences are pleased to announce today an exclusive license agreement to develop and commercialize JEN-101 (formerly known as cANK-101). JEN-101 is a first-in-class, pre-clinical immuno-oncology agent...
by Anand Patadiya | Sep 20, 2024
Ankyra Therapeutics will provide an update on the status of the ANK-101 Phase 1 ANCHOR clinical trial at ASCO 2024 and has received approval by FDA and Health Canada to amend the Phase I study to include patients with solid tumors in visceral organs June 1, 2024...
